Cargando…
Clinical utility of the INECO Frontal Screening for detecting Mild Cognitive Impairment in Parkinson’s disease
Cognitive deficits in Parkinson’s disease typically affect executive functions. Recently, the concept of Mild Cognitive Impairment (MCI) has been related to PD (PD-MCI). PD-MCI is considered a transition phase to Parkinson’s disease Dementia. Therefore, it is important to identify PD-MCI in a reliab...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Associação de Neurologia Cognitiva e do
Comportamento
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6907705/ https://www.ncbi.nlm.nih.gov/pubmed/31844492 http://dx.doi.org/10.1590/1980-57642018dn13-040005 |
_version_ | 1783478580887420928 |
---|---|
author | Broche-Pérez, Yunier Bartuste-Marrer, Danay Batule-Domínguez, Miriam Toledano-Toledano, Filiberto |
author_facet | Broche-Pérez, Yunier Bartuste-Marrer, Danay Batule-Domínguez, Miriam Toledano-Toledano, Filiberto |
author_sort | Broche-Pérez, Yunier |
collection | PubMed |
description | Cognitive deficits in Parkinson’s disease typically affect executive functions. Recently, the concept of Mild Cognitive Impairment (MCI) has been related to PD (PD-MCI). PD-MCI is considered a transition phase to Parkinson’s disease Dementia. Therefore, it is important to identify PD-MCI in a reliable way. Objective: To evaluate the sensitivity and specificity of the INECO Frontal Screening (IFS) in detecting cognitive deficits in PD-MCI. Additionally, we compare the IFS and the Addenbrook Cognitive Examination Revised (ACE-R) between three groups; PD-MCI, MCI, and controls. Methods: The IFS and ACE-R were administered to 36 patients with PD-MCI, 31 with MCI (amnestic-multidomain subtype) and 92 healthy controls. Sensitivity and specificity were determined using ROC analysis. The groups were compared using one-way analysis of variance. Results: The IFS had adequate accuracy in differentiating patients with PD-MCI from healthy controls (AUC=0.77, sensitivity=0.82, specificity=0.77), and good accuracy in differentiating PD-MCI from MCI patients (AUC=0.80, sensitivity=0.82, specificity=0.61). However the IFS had low accuracy in differentiating MCI patients from healthy controls (AUC=0.47, sensitivity=0.52, specificity=0.41). On the ACE-R, the PD-MCI group had low performance in Fluency and Language. Only patients with PD-MCI had difficulties on the IFS, specifically in inhibitory control and visual working memory. This dysexecutive profile explains the sensitivity and specificity values found in the IFS. Conclusion: The present study results suggest that the IFS is a suitable screening tool for exploring cognitive dysfunction in PD-MCI, especially in those patients with a dysexecutive profile. |
format | Online Article Text |
id | pubmed-6907705 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Associação de Neurologia Cognitiva e do
Comportamento |
record_format | MEDLINE/PubMed |
spelling | pubmed-69077052019-12-16 Clinical utility of the INECO Frontal Screening for detecting Mild Cognitive Impairment in Parkinson’s disease Broche-Pérez, Yunier Bartuste-Marrer, Danay Batule-Domínguez, Miriam Toledano-Toledano, Filiberto Dement Neuropsychol Original Article Cognitive deficits in Parkinson’s disease typically affect executive functions. Recently, the concept of Mild Cognitive Impairment (MCI) has been related to PD (PD-MCI). PD-MCI is considered a transition phase to Parkinson’s disease Dementia. Therefore, it is important to identify PD-MCI in a reliable way. Objective: To evaluate the sensitivity and specificity of the INECO Frontal Screening (IFS) in detecting cognitive deficits in PD-MCI. Additionally, we compare the IFS and the Addenbrook Cognitive Examination Revised (ACE-R) between three groups; PD-MCI, MCI, and controls. Methods: The IFS and ACE-R were administered to 36 patients with PD-MCI, 31 with MCI (amnestic-multidomain subtype) and 92 healthy controls. Sensitivity and specificity were determined using ROC analysis. The groups were compared using one-way analysis of variance. Results: The IFS had adequate accuracy in differentiating patients with PD-MCI from healthy controls (AUC=0.77, sensitivity=0.82, specificity=0.77), and good accuracy in differentiating PD-MCI from MCI patients (AUC=0.80, sensitivity=0.82, specificity=0.61). However the IFS had low accuracy in differentiating MCI patients from healthy controls (AUC=0.47, sensitivity=0.52, specificity=0.41). On the ACE-R, the PD-MCI group had low performance in Fluency and Language. Only patients with PD-MCI had difficulties on the IFS, specifically in inhibitory control and visual working memory. This dysexecutive profile explains the sensitivity and specificity values found in the IFS. Conclusion: The present study results suggest that the IFS is a suitable screening tool for exploring cognitive dysfunction in PD-MCI, especially in those patients with a dysexecutive profile. Associação de Neurologia Cognitiva e do Comportamento 2019 /pmc/articles/PMC6907705/ /pubmed/31844492 http://dx.doi.org/10.1590/1980-57642018dn13-040005 Text en https://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Broche-Pérez, Yunier Bartuste-Marrer, Danay Batule-Domínguez, Miriam Toledano-Toledano, Filiberto Clinical utility of the INECO Frontal Screening for detecting Mild Cognitive Impairment in Parkinson’s disease |
title | Clinical utility of the INECO Frontal Screening for detecting Mild
Cognitive Impairment in Parkinson’s disease |
title_full | Clinical utility of the INECO Frontal Screening for detecting Mild
Cognitive Impairment in Parkinson’s disease |
title_fullStr | Clinical utility of the INECO Frontal Screening for detecting Mild
Cognitive Impairment in Parkinson’s disease |
title_full_unstemmed | Clinical utility of the INECO Frontal Screening for detecting Mild
Cognitive Impairment in Parkinson’s disease |
title_short | Clinical utility of the INECO Frontal Screening for detecting Mild
Cognitive Impairment in Parkinson’s disease |
title_sort | clinical utility of the ineco frontal screening for detecting mild
cognitive impairment in parkinson’s disease |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6907705/ https://www.ncbi.nlm.nih.gov/pubmed/31844492 http://dx.doi.org/10.1590/1980-57642018dn13-040005 |
work_keys_str_mv | AT brocheperezyunier clinicalutilityoftheinecofrontalscreeningfordetectingmildcognitiveimpairmentinparkinsonsdisease AT bartustemarrerdanay clinicalutilityoftheinecofrontalscreeningfordetectingmildcognitiveimpairmentinparkinsonsdisease AT batuledominguezmiriam clinicalutilityoftheinecofrontalscreeningfordetectingmildcognitiveimpairmentinparkinsonsdisease AT toledanotoledanofiliberto clinicalutilityoftheinecofrontalscreeningfordetectingmildcognitiveimpairmentinparkinsonsdisease |